Table 3. Medications between the Two Groups.
| Variables, n (%) | Entire patients | Matched patients | ||||
|---|---|---|---|---|---|---|
| Diltiazem (n=842) | Dual (n=1899) | p value | Diltiazem (n=811) | Dual (n=811) | p value | |
| Trimetazidine | 471 (55.9) | 1154 (60.7) | 0.018 | 458 (56.4) | 449 (55.3) | 0.653 |
| Molsidomine | 47 (5.5) | 157 (8.2) | 0.013 | 47 (5.7) | 46 (5.6) | 0.915 |
| Beta blockers | 80 (9.5) | 144 (7.5) | 0.091 | 70 (8.6) | 66 (8.1) | 0.720 |
| Diuretics | 67 (7.9) | 178 (9.3) | 0.231 | 65 (8.0) | 56 (6.9) | 0.395 |
| ARB | 96 (11.4) | 336 (17.6) | <0.001 | 95 (11.7) | 92 (11.3) | 0.816 |
| ACEI | 31 (3.6) | 67 (3.5) | 0.842 | 30 (3.6) | 36 (4.4) | 0.451 |
| Aspirin | 113 (13.4) | 279 (14.6) | 0.380 | 108 (13.3) | 119 (14.6) | 0.431 |
| Clopidogrel | 42 (4.9) | 89 (4.6) | 0.733 | 39 (4.8) | 38 (4.6) | 0.907 |
| Cilostazol | 18 (2.1) | 37 (1.9) | 0.744 | 17 (2.0) | 13 (1.6) | 0.461 |
| Warfarin | 11 (1.3) | 19 (1.0) | 0.478 | 11 (1.3) | 13 (1.6) | 0.681 |
| Statins | 306 (36.3) | 845 (44.4) | <0.001 | 300 (36.9) | 310 (38.2) | 0.608 |
ARB, angiotensin receptor blockers; ACEI, angiotensin converting enzyme inhibitors.